OHARA Pharmaceutical Co.,Ltd.

Entirely from the patients' perspective Providing dependable pharmaceuticals for the future of medicine Ohara Pharmaceutical Co.,Ltd.

November 14, 2018: A development project for a novel therapeutic agent for liver cirrhosis was adopted as the Cyclic Innovation for Clinical Innovation for Clinical Empowerment(CiCLE) by the Japan Agency for Medical Research and Development(AMED) (PDF: 188KB)
June 21, 2018: Ohara has entered into license agreement with PRISM on novel liver cirrhosis treatment (PDF: 116KB)
September 13, 2017: A Cooperative Research Study with the National Cancer Center Japan (PDF: 1.03MB)
February 14, 2017: Postponement of the NHI Drug Price Listing and Launch of "ERWINASE^® for intramuscular injection 10000" (PDF: 129KB)
December 19, 2016: Acquisition of Marketing Approval in Japan for "ERWINASE^® for intramuscular injection 10000" (PDF: 168KB)